Exagen Inc

NASDAQ:XGNUnited States

Nov 12, 2024

Show headlines and story abstract

• -- Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.5M, from 8:08AM ET on Tuesday Nov 12, 2024 by MT Newswires

  8:08AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: XGN
  08:08 AM EST, 11/12/2024 (MT Newswires) -- ...

• Exagen Inc. Reports Third Quarter 2024 Results, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: XGN
  
  Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen's goals, strategies and ambitions; potential future financial and business performance; the potential utility and effectiveness of Exagen's services and testing solutions; updates to be made to AVISE(R) CTD; potential shareholder value and growth and full-year 2024 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen's business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; changes in laws and regulations related to Exagen's regulatory requirements; Exagen's commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen's ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen's testing products, including Exagen's ability to collect on funds due; Exagen's ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen's business; and other risks described in Exagen's prior press releases and Exagen's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in Exagen's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 18, 2024, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 12, 2024 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  

• *DJ Exagen 3Q Loss/Shr 28c >XGN, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: XGN